Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.
Identifieur interne : 001022 ( PubMed/Corpus ); précédent : 001021; suivant : 001023Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.
Auteurs : P. Pollak ; F. Tison ; O. Rascol ; A. Destée ; J J Péré ; J M Senard ; F. Durif ; I. BourdeixSource :
- Journal of neurology, neurosurgery, and psychiatry [ 0022-3050 ] ; 2004.
English descriptors
- KwdEn :
- Aged, Clozapine (administration & dosage), Clozapine (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Feasibility Studies, Female, Follow-Up Studies, GABA Antagonists (administration & dosage), GABA Antagonists (adverse effects), Humans, Levodopa (adverse effects), Male, Parkinson Disease (drug therapy), Prospective Studies, Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (etiology).
- MESH :
- chemical , administration & dosage : Clozapine, GABA Antagonists.
- chemical , adverse effects : GABA Antagonists, Levodopa.
- chemical , therapeutic use : Clozapine.
- diagnosis : Psychoses, Substance-Induced.
- drug therapy : Parkinson Disease.
- etiology : Psychoses, Substance-Induced.
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Prospective Studies.
Abstract
To compare the efficacy and safety of clozapine in drug induced psychosis in Parkinson's disease (PD).
PubMed: 15090561
Links to Exploration step
pubmed:15090561Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.</title><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name><affiliation><nlm:affiliation>Department of Neurology, University Hospital of Grenoble, 38043 Grenoble Cedex 9, France. pierre.pollak@ujf-grenoble.fr</nlm:affiliation></affiliation></author><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author><author><name sortKey="Pere, J J" sort="Pere, J J" uniqKey="Pere J" first="J J" last="Péré">J J Péré</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15090561</idno><idno type="pmid">15090561</idno><idno type="wicri:Area/PubMed/Corpus">001022</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001022</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.</title><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name><affiliation><nlm:affiliation>Department of Neurology, University Hospital of Grenoble, 38043 Grenoble Cedex 9, France. pierre.pollak@ujf-grenoble.fr</nlm:affiliation></affiliation></author><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author><author><name sortKey="Pere, J J" sort="Pere, J J" uniqKey="Pere J" first="J J" last="Péré">J J Péré</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Clozapine (administration & dosage)</term><term>Clozapine (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Feasibility Studies</term><term>Female</term><term>Follow-Up Studies</term><term>GABA Antagonists (administration & dosage)</term><term>GABA Antagonists (adverse effects)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Parkinson Disease (drug therapy)</term><term>Prospective Studies</term><term>Psychoses, Substance-Induced (diagnosis)</term><term>Psychoses, Substance-Induced (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Clozapine</term><term>GABA Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>GABA Antagonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Clozapine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Feasibility Studies</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Prospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To compare the efficacy and safety of clozapine in drug induced psychosis in Parkinson's disease (PD).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15090561</PMID><DateCreated><Year>2004</Year><Month>04</Month><Day>19</Day></DateCreated><DateCompleted><Year>2004</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.</ArticleTitle><Pagination><MedlinePgn>689-95</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the efficacy and safety of clozapine in drug induced psychosis in Parkinson's disease (PD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A four week, randomised, double blind, parallel comparison of clozapine and placebo, followed by a 12 week clozapine open period, plus a one month period after drug discontinuation, in 60 patients with PD. The primary efficacy outcome was the "clinical global impression scale" (CGI); the positive subscore of the "positive and negative syndrome scale" (PANSS) was used as the secondary efficacy parameter and the "unified Parkinson's disease rating scale" (UPDRS) and the "mini mental test examination" (MMSE) as safety outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean (SD) dosage of clozapine was 35.8 (12.5-50) mg at the end of the double blind period. The mean (SD) scores on the CGI improved by 1.8 (1.5) for the clozapine group compared with 0.6 (1.1) for the placebo group (p = 0.001). The mean (SD) positive subscore of PANSS improved by 5.6 (3.9) for the clozapine group (0.8 (2.8) for the placebo group; p < 0.0001). At the end of the open period, 25 patients had completely recovered from delusions and hallucinations, and 19 experienced a relapse within one month after the clozapine washout period. The UPDRS motor and MMSE mean scores did not change significantly in either group. Somnolence was more frequent with clozapine than with placebo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clozapine at a mean dose lower than 50 mg/day improves drug induced psychosis in PD without significant worsening of motor function, and the effect wears off once the treatment stops.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Grenoble, 38043 Grenoble Cedex 9, France. pierre.pollak@ujf-grenoble.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tison</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Destée</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Péré</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Senard</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bourdeix</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018756">GABA Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Mar;15(2):201-11</RefSource><PMID Version="1">10752567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Sep 26;55(6):748-9</RefSource><PMID Version="1">10993989</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Arch Psychiatry Neurol Sci. 1985;235(1):60-4</RefSource><PMID Version="1">2864254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Psychiatry Suppl. 1989 Nov;(7):59-67</RefSource><PMID Version="1">2619982</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1990 May;40(5):832-4</RefSource><PMID Version="1">1970427</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1991 Aug;14(4):283-95</RefSource><PMID Version="1">1680556</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1993;60:703-6</RefSource><PMID Version="1">8420214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1993 Jul 15;329(3):162-7</RefSource><PMID Version="1">8515788</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Park Dis Dement Sect. 1993;5(2):135-46</RefSource><PMID Version="1">8333909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1994 May;9(3):350-2</RefSource><PMID Version="1">8041379</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1995;65:115-38</RefSource><PMID Version="1">7872135</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1995 Apr;45(4):669-71</RefSource><PMID Version="1">7723953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 1996 Summer;8(3):276-80</RefSource><PMID Version="1">8854298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 1997;104(11-12):1305-11</RefSource><PMID Version="1">9503276</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1998 Sep-Oct;21(5):280-4</RefSource><PMID Version="1">9789707</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1999 Mar 11;340(10):801-3</RefSource><PMID Version="1">10072418</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1999;52(7 Suppl 3):S10-3</RefSource><PMID Version="1">10227604</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1999;52(7 Suppl 3):S14-6</RefSource><PMID Version="1">10227605</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1999 May;56(5):595-601</RefSource><PMID Version="1">10328255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Psychiatr Res. 1975 Nov;12(3):189-98</RefSource><PMID Version="1">1202204</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018756" MajorTopicYN="N">GABA Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1763590</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15090561</ArticleId><ArticleId IdType="pmc">PMC1763590</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001022 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001022 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15090561
|texte= Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15090561" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |